Sequencing radium 223 and other life-prolonging agents in castration-resistant prostate cancer patients.
- Caffo O
- Frantellizzi V
- Monari F
- Sbrana A
- Costa RP
- Pinto C
- Tucci M
- Baldari S
- Facchini G
- Bortolus R
- Alongi F
- Alongi P
- Palermo A
- Fanti S
- Biasco E
- Murabito A
- Filice A
- Zichi C
- Pignata S
- Borsatti E
- Salgarello M
- Spada M
- Cortesi E
- Vincentis G.
DOIAbstract
Background: Radium 223 (RA223) is currently administered as part of a therapeutic sequence with the other life-prolonging agents (LPAs) for metastatic castration-resistant prostate cancer (mCRPC). Patients & methods: We retrospectively reviewed the clinical records of patients who had received at least three LPAs including RA223. Results: Median overall survival (OS) from the start of first-line treatment was 39.8 months, with the patients who completed all six planned courses of RA223 having a longer OS than those who did not (53.2 vs 29.5 months; p < 0.0001). Conclusions: Our study confirms the activity of RA223 regardless of the treatment line in which it is administered and suggests that patient selection plays a central role in ...
Add to ORKG